Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes

Journal of Investigative Dermatology Symposium Proceedings

Volumn 12, Issue 1, 2007, Pages 9-15

  Haider, Asifa S ^a   Cardinale, Irma R ^a   Whynot, Julia A ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12 RECEPTOR BETA2;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE REPRESSION; GENETIC REGULATION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; LEUKOCYTE ACTIVATION; NUCLEOTIDE SEQUENCE; PRIMARY IMMUNE RESPONSE;

ANTIBODIES, MONOCLONAL; BASE SEQUENCE; DNA PRIMERS; DOWN-REGULATION; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; LEUKOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248546506     PISSN: 10870024     EISSN: 15291774     Source Type: Journal    
DOI: 10.1038/sj.jidsymp.5650032     Document Type: Article

References (21)

1. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P et al. (2005) Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 102:2075-80
2. Cristillo ADM, Macri J, Bierer BE (2003) Differential chemokine expression profiles in human peripheral blood T lymphocytes: dependence on T-cell coreceptor and calcineurin signaling. Blood 101:216-25
3. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J et al. (2004) The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50:2750-6
4. Franscini N, Blau N, Walter RB, Schaffner A, Schoedon G (2003) Critical role of interleukin-1beta for transcriptional regulation of endothelial 6-pyruvoyltetrahydropterin synthase. Arterioscler Thromb Vasc Biol 23:e50-3
5. Gottlieb AB (2005) Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 4:19-34
6. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA et al. (2005) TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175:2721-9
7. Haider ASS, Peters B, Kaporis H, Cardinale I, Fei J, Ott J et al. (2006) Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol 126:869-81
8. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wag J et al. (1999) Selective recruitment of CCR4-bearing Th2 cells towards antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 11:81-8
9. Jenmalm MC, Van Snick J, Cormont F, Salman B (2001) Allergen-induced Th1 and Th2 cytokine secretion in relation to specific allergen sensitization and atopic symptoms in children. Clin Exp Allergy 31:1528-35
10. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-104
11. Klunker S, Trautmann A, Akdis M, Verhagen J, Schmid-Grendelmeier P, Blaser K et al. (2003) A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J Immunol 171:1078-84
12. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M et al. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443-53
13. Maghazachi AA, Skalhegg BS, Rolstad B, Al-Aoukaty A (1997) Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins. FASEB J 11:765-74
14. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP et al. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-61
15. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-26
16. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH et al. (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61:361-70
17. Sumyoshi K, Nakao A, Setoguchi Y, Tsuboi R, Okumura K, Ogawa H (2003) TGF-beta/Smad signaling inhibits IFN-gamma and TNF-alpha-induced TARC (CCL17) production in HaCaT cells. J Dermatol Sci 31:53-8
18. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM et al. (2001) Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167:1072-80
19. Uchida T, Suto H, Ra C, Ogawa H, Kobata T, Okumura K (2002) Preferential expression of T(h)2-type chemokine and its receptor in atopic dermatitis. Int Immunol 14:1431-8
20. Williams KLA, Zullo J, Kaplan MH, Brutkiewicz RR, Deppmann CD, Vinson C et al. (2003) BATF transgenic mice reveal a role for activator protein-1 in NKT cell development. J Immunol 170:2417-26
21. Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi S, Yoshie O (1998) Identification of single C motif-1/lymphotactin receptor XCR1. J Biol Chem 273:16551-4